AIR CARG O WEEK


CARGO TECHNOLOGY


SKYCELL CLOSES SIGNIFICANT FUNDING EFFORT


S


“This means for a typical pharma customer today we save more than 250,000 tonnes of CO2 every year without compromising quality”


kyCell, a Swiss technology company revolutionising the pharmaceutical supply chain with its hybrid containers, has closed its $116 million Series D funding round, securing $59 million from Tybourne Capital Management and CC Industries. This latest round of funding solidifies


SkyCell’s position as one of Europe’s leading deeptech companies amid the rapid growth of the pharmaceutical industry, driven by high-value biologics that require meticulous transportation. SkyCell employs a multifaceted strategy to safeguard the pharmaceutical supply chain,


integrating temperature-controlled


containers, sophisticated software, and big data analytics. Each month, SkyCell containers protect over $2.5 billion worth of pharmaceutical products, including millions of vaccine doses, cancer treatments, diabetes care, and diagnostic solutions transported by air globally. The company’s proprietary cold chain technology, combined


with its SkyMind software platform, underpins its success in maintaining


the integrity of pharmaceutical goods. SkyMind


enhances shipment and asset management through automation and real-time visibility, enabling pharmaceutical companies and their suppliers to optimise supply chain decisions based on risk, cost, and carbon dioxide emissions. With access to historical data from its extensive fleet of connected


containers and advanced predictive analytics, SkyMind significantly improves the predictability and prevention of medication loss. Part of this software suite includes the Decarbonise tool, which allows clients to forecast, track and report CO2 emissions, as well as optimise transportation routes to minimise their carbon footprint. The new investment will fuel SkyCell’s global expansion, with


a particular focus on growth in the US and Asia. This strategic expansion aims to enhance the company’s ability to protect high- value pharmaceutical goods across increasingly complex global supply chains. Welcoming the new investment, Richard Ettl, co-founder and


CEO of SkyCell, said: “It is such an exciting time to be a technology provider to the pharma industry as the sector experiences fast growth from new, blockbuster biologics coming to market. At the


10


same time, the industry has recognised the need to decarbonise the supply chain, as more than 70% of pharma is shipped in a one-way solution, which will shortly see fees introduced for disposal. Our reusable 1500X container saves on average 50% CO2 or in absolute terms eight tonnes CO2e per use. “This means for a typical pharma customer today we save more


than 250,000 tonnes of CO2 every year without compromising quality. And finally, digitalisation is coming to pharma supply chains – moving away from manual worksheets to integrated workflows that leverage S+O data (simulated and operational data) from our proprietary pool of billions of data points. Combined with the power of AI, this enables significant reductions in both cost and risk for our customers. With this new investment, we can further optimise supply chains and create truly sustainable logistics.” SkyCell is a purpose-led technology company transforming the


pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It is the leading manufacturer of temperature-controlled door-to-door container solutions that allow pharma companies to optimise their supply chain by reducing and even predicting the risks associated with delivering sensitive drugs by air. Its proprietary software solution combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world getting life-changing drugs to consumers faster. SkyCell’s


technologies are designed with sustainability at


their core, significantly reducing the risk of in-transit failure and minimising environmental impact. With a market-leading low rate of less than 0.05% temperature excursions, SkyCell’s solutions ensure the integrity of healthcare shipments. Additionally, the company’s innovative containers cut the CO2 emissions of each shipment by nearly 50% compared to the average rate. SkyCell operates as a climate-neutral company (Scope 1 and 2


compensated) and is committed to achieving end-to-end net-sero emissions by 2040. Its sustainability goals are science-driven and aligned with the Paris Agreement and the United Nations Sustainable Development Goals, underscoring its dedication to both environmental responsibility and global health.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14